Shots:

• The last patient is out from the P-IIb part of its multinational P-IIb/III study of NP-120 for the COVID-19 has now completed treatment with 2wk follow up
• The company reports positive interim results for the P-IIb part of it P-IIb/III Ifenprodil COVID-19 study and expecting the final data set by end of Feb 2021
• NP-120 (Ifenprodil) is an NMDA receptor antagonist specifically targeting the NMDA-type subunit 2B- & prevents glutamate signaling. The NMDA receptor is found on many tissues including lung cells- T-cells & neutrophils

 ­ Ref: GlobeNewswire  | Image: Algernon